J Korean Ophthalmol Soc > Volume 49(12); 2008 > Article
Journal of the Korean Ophthalmological Society 2008;49(12):1901-1909.
DOI: https://doi.org/10.3341/jkos.2008.49.12.1901    Published online December 15, 2008.
Clinical Results After Application of Bevacizumab in Recurrent Pterygium.
Jong Wook Lee, Young Jeung Park, In Taek Kim, Kyoo Won Lee
1Cheil Eye Hospital, Daegu, Korea. eyepark9@dreamwiz.com
2Department of Ophthalmology, School of Medicine, Kyungpook National University, Daegu, Korea.
재발성군날개 치료에 있어 항혈관내피성장인자 항체 베바시주맙을 적용한 임상효과
이종욱1ㆍ박영정1ㆍ김인택2ㆍ이규원1
Cheil Eye Hospital1, Daegu, Korea / Department of Ophthalmology, School of Medicine, Kyungpook National University2, Daegu, Korea
Abstract
PURPOSE
To clinically establish the effectiveness and safety of bevacizumab on recurrent pterygium. METHODS: Twenty patients with recurrent pterygium were given a subconjunctival injection of 0.3 cc bevacizumab, and were evaluated for periodic clinical results at 1 week, 2 weeks, 4 weeks, and every month thereafter. The patients were also evaluated for clinical results and complications. RESULTS: Of recurrent pterygium patients with bevacizumab injection, the conjunctival injection decreased maximally after 1 to 2 weeks, but significantly increased at 4 weeks (above the lowest level measured at 1 to 2 weeks), and no patient presented conjunctival injection above the pre-injection level at 3 months, except in 2 cases. Two weeks after the injection, ICG anterior segment angiography revealed a significant decrease (30.14+17.69%) in vessel thickness of the pterygium 2 weeks after the bevacizumab injection compared to before the injection. There had been no cases of progression of pterygium, and no ocular or systemic complications due to bevacizumab. CONCLUSIONS: As shown above in the results, subconjunctival injection of 0.3 cc bevacizumab decreased the conjunctival injection and effectively suppressed any further progression of pterygium. Thus, bevacizumab subconjunctival injection appears to be effective in recurrent pterygium treatment instead of surgical methods.
Key Words: Bevacizumab;Recurrent pterygium;Subconjunctival injection


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next